LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours
March 21, 2023 08:46 ET
|
LIfT BioSciences
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours IMANp is the world’s first neutrophil-based cell...
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours
March 21, 2023 03:00 ET
|
LIfT BioSciences
LIfT BioSciences announces breakthrough preclinical data demonstrating the dual mode of action commonly believed necessary for curing solid tumours IMANp is the world’s first neutrophil-based cell...
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS
December 19, 2022 07:00 ET
|
LIfT BioSciences
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for N-LIfT to enter the clinic by Q1 2024 London, 19...
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS
December 19, 2022 02:00 ET
|
LIfT BioSciences
LIfT BioSciences investors increase investment in LIfT and Johnson and Johnson welcomes LIfT into JLABS Additional investment supports plans for N-LIfT to enter the clinic by Q1 2024 London, 19...
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models
September 14, 2022 07:00 ET
|
LIfT BioSciences
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models London, 14th September 2022 – LIfT BioSciences today...
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models
September 14, 2022 02:00 ET
|
LIfT BioSciences
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models London, 14th September 2022 – LIfT BioSciences today...
LIfT BioSciences N-LIfT cell therapy shows complete and superior cell killing in solid tumour organoids compared to Keytruda
April 06, 2022 02:00 ET
|
LIfT BioSciences
LIfT BioSciences N-LIfT cell therapy shows complete and superior cell killing in solid tumour organoids compared to Keytruda Research reinforces the value of using Tumouroid models as efficacy...
LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo
November 09, 2020 02:00 ET
|
LIfT BioSciences
LIfT BioSciences N-LIfT Cell Therapy Successfully Infiltrates Pancreatic Tumours In-vivo London, 9 November 2020 –LIfT BioSciences, a biotech company developing a first in class innate cell...